BIEBER, T. .; BECK, L.; PINK, A.; SAEKI, H.; EICHENFELD, L.; WERFEL, T.; ROSHOLM, A.; ROPKE, M.; PALLER, A. . Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 6, p. s56, 2021. DOI: 10.25251/skin.5.supp.56. Disponível em: Acesso em: 13 aug. 2022.